AstraZeneca AB v. Zydus Cadila — LYNPARZA® Olaparib Patent Consolidated
AstraZeneca asserted U.S. Patent No. 12,178,816, covering olaparib tablets marketed as LYNPARZA®, against generic challenger Zydus Cadila in the District of New Jersey. Within 148 days of filing, the case was consolidated with a broader multi-defendant docket (23-cv-796), centralising pre-trial proceedings for at least four related olaparib patent suits filed simultaneously.
Filing to Case Consolidated in 148 days
148 days from filing to consolidation order — rapid procedural resolution consistent with ANDA multi-suit coordination
Case consolidated into 23-cv-796: what the order means for both parties
Consolidation under Fed. R. Civ. P. 42(a) — not a dismissal
When a district court consolidates cases, the individual dockets are merged into a single proceeding for pre-trial and, potentially, trial purposes. This case (3:25-cv-234) was not dismissed — it was absorbed into lead docket 23-cv-796 alongside at least three other newly filed olaparib actions. All substantive claims remain live; the consolidation is a case-management tool to reduce duplication and coordinate discovery and claim construction.
Claims remain activeAstraZeneca gains unified enforcement platform for the ‘816 patent
Consolidation typically benefits the originator plaintiff in ANDA litigation by aligning scheduling across multiple generic challengers. AstraZeneca can coordinate claim construction and infringement contentions for U.S. Patent No. 12,178,816 — which issued as recently as December 31, 2024 — across all defendants simultaneously, reducing the risk of inconsistent rulings and streamlining its enforcement of the newly granted ‘816 patent.
Coordinated enforcementZydus Cadila faces a broader multi-defendant consolidated proceeding
Consolidation places Zydus Cadila in a joint litigation track with other generic challengers of olaparib patents. While this can create cost efficiencies, it also means discovery, claim construction, and contentions schedules are set collectively. The court’s indication that future claim narrowing will be required signals that defendants should expect active case management pressure to focus their invalidity and non-infringement arguments.
Multi-defendant trackLate-filing ‘816 patent extends LYNPARZA® litigation horizon
U.S. Patent No. 12,178,816 issued on December 31, 2024 — a recently granted patent asserted within weeks of issuance. This suggests AstraZeneca’s strategy of layering newer patents onto existing ANDA litigation to extend the period of exclusivity dispute for LYNPARZA®. Generic entry timelines for olaparib tablets remain contested, and the consolidated proceeding’s outcome will likely set the market entry date for multiple filers simultaneously.
Exclusivity extension riskFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | AstraZeneca AB | Individual | Search in Eureka ↗ |
| Defendant | Zydus Cadila | Individual | Search in Eureka ↗ |
| Plaintiff counsel | Charles H. Chevalier | Attorney | Counsel for AstraZeneca ABSearch in Eureka ↗ |
| Plaintiff law firm | Gibbons PC | Law Firm | Representing AstraZeneca ABSearch in Eureka ↗ |
| Defendant counsel | ALEC WONG | Attorney | Counsel for Zydus CadilaSearch in Eureka ↗ |
| Defendant counsel | Lauren Brophy Cooper | Attorney | Counsel for Zydus CadilaSearch in Eureka ↗ |
| Defendant counsel | Theodora T. Mccormick | Attorney | Counsel for Zydus CadilaSearch in Eureka ↗ |
| Defendant law firm | Baker, Donelson, Bearman, Caldwell & Berkowitz PC | Law Firm | Representing Zydus CadilaSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The May 5, 2025 consolidation order is procedural, not substantive — it does not resolve infringement or validity of U.S. Patent No. 12,178,816. The court’s direction to follow L.Pat.R. 3.6 standard contentions order preserves both parties’ full claim sets while imposing a disciplined schedule. The court’s anticipation of future claim narrowing suggests active judicial management is likely, which typically accelerates settlement discussions in multi-defendant ANDA proceedings.
US12178816B2 — Olaparib tablet formulation (LYNPARZA®)
U.S. Patent No. 12,178,816 (application no. US18/785063) covers olaparib tablet formulations at 100 mg and 150 mg dosages, the active ingredient in AstraZeneca’s LYNPARZA® — a PARP inhibitor approved for multiple BRCA-mutated cancers including ovarian, breast, and prostate. Notably, this patent issued on December 31, 2024, indicating a late-prosecution grant strategy common in lifecycle management of blockbuster oncology drugs.
The strategic significance of the ‘816 patent lies in its recency: asserting a newly issued patent in ANDA proceedings can reset or extend the 30-month stay clock and complicate generic challengers’ invalidity preparations. For the oncology sector, where LYNPARZA® commands significant revenues, any delay in generic entry has material commercial consequences. Competitors developing olaparib generics must assess whether their formulations fall within the ‘816 patent’s claim scope and review its prosecution history for file wrapper estoppel opportunities.
Should your olaparib generic programme run an FTO against US12178816B2?
Any company with an ANDA or 505(b)(2) application referencing olaparib tablets at 100 mg or 150 mg should treat U.S. Patent No. 12,178,816 as a live FTO risk. Issued in December 2024 and asserted within one month, it represents the most recent addition to AstraZeneca’s olaparib patent estate. Generic manufacturers, contract pharmaceutical developers, and oncology biosimilar teams should determine whether their formulation falls within its claims before advancing regulatory or commercial timelines.
PatSnap Eureka’s FTO Search Agent can map U.S. Patent No. 12,178,816 against your olaparib formulation parameters, identify overlapping claims across AstraZeneca’s broader LYNPARZA® patent family, flag co-pending applications that may issue as continuation patents, and surface prior art relevant to invalidity arguments. Running a structured FTO now — before claim construction is set in the consolidated proceeding — is the highest-leverage point to inform both litigation defence and ANDA strategy.
Run a freedom-to-operate analysis on US12178816B2 to assess your product’s exposure
Run FTO in Eureka →Related PARP inhibitor and oncology ANDA patent cases in NJ District Court
Explore consolidated and related olaparib ANDA patent suits filed in the District of New Jersey, including co-pending dockets under lead case 23-cv-796.
What this case signals for the oncology ANDA IP landscape
AstraZeneca’s rapid assertion of a newly issued olaparib patent illustrates how late-stage patent prosecution can reshape generic entry timelines.
Newly issued patents can be asserted within weeks — monitor issuances closely
The ‘816 patent issued December 31, 2024 and was asserted in January 2025. Generic manufacturers and patent challengers must monitor issuances in their therapeutic category in near-real time. A 30-month stay triggered by a late-issuing patent can significantly delay FDA approval of an ANDA even when earlier patents in the same family have been resolved.
Consolidation signals the court’s intent to manage olaparib generics collectively
Consolidating at least five related olaparib dockets into 23-cv-796 indicates the District of New Jersey is treating this as a coordinated ANDA proceeding. Companies tracking generic olaparib entry should monitor the lead docket — any claim construction ruling there will bind all consolidated defendants simultaneously.
AB v Zydus — key questions answered
The District of New Jersey consolidated case 3:25-cv-00234 into lead docket 23-cv-796 on May 5, 2025. AstraZeneca had asserted U.S. Patent No. 12,178,816 — covering LYNPARZA® olaparib tablets — against Zydus Cadila. The consolidation merges pre-trial proceedings with at least four related olaparib suits; substantive claims remain active.
U.S. Patent No. 12,178,816 (application US18/785063) covers olaparib tablet formulations at 100 mg and 150 mg dosages — the active ingredient in AstraZeneca’s LYNPARZA®, a PARP inhibitor used in BRCA-mutated cancers. It issued on December 31, 2024, making it one of the most recently granted patents in AstraZeneca’s olaparib lifecycle management portfolio.
Consolidation into 23-cv-796 means that claim construction, discovery, and likely trial for multiple olaparib generics will proceed on a unified schedule set by the court. Any ruling on infringement or validity of the ‘816 patent will apply to all consolidated defendants. This collective proceeding typically prolongs uncertainty around generic entry dates until a final resolution is reached.
Asserting a newly issued patent in ongoing or parallel ANDA litigation is a recognised lifecycle management strategy. It can trigger a new 30-month stay under the Hatch-Waxman Act if the ANDA filer has not yet listed the patent in a Paragraph IV certification, and it expands the scope of claims AstraZeneca can enforce. Filing within weeks of issuance is consistent with a strategy of maximising exclusivity protection for LYNPARZA®.
AstraZeneca is represented by Gibbons PC, with attorney Charles H. Chevalier named on the filing. Zydus Cadila is represented by Baker, Donelson, Bearman, Caldwell & Berkowitz PC, with attorneys Alec Wong, Lauren Brophy Cooper, and Theodora T. McCormick listed on the defence side.
PatSnap Eureka searches patents and litigation data to answer instantly.